1 / 16

EUROPEAN RESEARCH AND INNOVATION OFFICE

EUROPEAN RESEARCH AND INNOVATION OFFICE. 4 th FLUTCORE Progress Meeting September 23 rd 2015 – London WP9 - Project Management Amelie Guisseau UCL European Research and Innovation Office a.guisseau@ucl.ac.uk. Project Management. Period 1 (M1-M18) Report update Finance summary

hannigan
Download Presentation

EUROPEAN RESEARCH AND INNOVATION OFFICE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EUROPEAN RESEARCH AND INNOVATION OFFICE 4th FLUTCORE Progress Meeting September 23rd 2015 – London WP9 - Project Management Amelie Guisseau UCL European Research and Innovation Office a.guisseau@ucl.ac.uk

  2. Project Management • Period 1 (M1-M18) Report update • Finance summary • Project deliverables (Period 2) • Dissemination reminders

  3. Period 1 report

  4. Periodic Report 1 (September 2013 – February 2015) • Period 1 report submitted on 30/04/2015 (within the deadline) • Administrative & scientific comments received 08/05/2015 • Responses from the consortium were sent on 11/05/2015 • Payment for the first reporting period was received on 08/06/2015 and distributed to partners in July A big thank you to you and your colleagues for your excellent collaboration with this report!

  5. Finance summary • Total costs declared and accepted in P1: €1,347,812.37 • Accepted EC contribution for P1: €1,032,774.02 • Interim Payment of €1,032,774.02 received on 08/06/2015 • We have now received (Pre-financing + Interim Payment 1) ~ 65% of the project’s total EC contribution • The next payment - following approval of Period 2 report (~November 2016) - will be limited to 85% of the maximum EC contribution. The remaining 15% will be paid at the end of the project (i.e. balance between the total accepted eligible costs minus the amounts already paid) • All partners have to anticipate a negative cash flow at the end of the project!

  6. Project monitoring

  7. Interim reporting (M19-M24)

  8. Interim reporting (M19-M24) 40% 32% Annex 1: Personnel: 40% Subcontracting: 13% Consumables: 18% Travels: 1% Other: 3% Indirect: 25% 2% 2% 16% 8%

  9. Interim reporting (M19-M24) 108% 4% 1% 68% 122% 39% 0% 62% 4%

  10. Project monitoring & where we are at M25 Y3 Y2 deliverables pending

  11. Pending deliverables: due M24 • D1.5, Robust method for efficient purification of recombinant VLPs suitable for transferring to a contract manufacturer – to be delivered shortly after the Tech transfer run at UCL • D3.4, Identification of the most immunogenic/protective VLP-NP construct in mice – put on hold – • D3.5, Go/NoGo decision based on a short list of the most immunogenic/protective VLP-HA/M2/NP in mice – completed, to be submitted shortly • D3.6, Identification of a protective CDR3 heavy chain signature in B cells – to be delivered end of September • D3.7, Identification of the protective TCR usage signature – to be delivered end of September • D4.1, Demonstration of efficacious prophylactic regimen of best candidate VLP in ferrets – WP4 start delayed • D4.2, Clinical lead candidate selected – WP4 start delayed • D5.1, Technical transfer documentation – in process, to be delivered shortly after the Tech transfer run at UCL .

  12. Plan for Y3: deliverables up to M30 • D2.4, Long-term stability data for VLPs • D5.2, MCB and WCB generated and fully characterised • D5.3, material made available for (a) preclinical toxicology (b) seroconversion and (c) structural analysis • D6.1, Final version of trial protocol as submitted to Ethical committee • D6.2, Preclinical safety report • D6.3, Regulatory application • D6.4, Appointment of the Ethics Advisor • D8.3, Exploitation plan – draft to be circulated by end of September

  13. Dissemination

  14. Dissemination: reminders • The project exploitation plan is due in September • Visibility of EU funding: All publications or any other dissemination relating to foreground must • Display the EU emblem (flag) • Include the following text The research leading to these results has received funding from the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement n° 602437. • Alldissemination activities related to FLUTCORE must be listed on the participant portal

  15. Publications • At least 45 days prior notice of any dissemination activity shall be given to the other beneficiaries concerned • Special clause 39: Open Access • a machine-readable electronic copy of the published version or final peer-reviewed manuscript accepted for publication shall be deposited in a repository (institutional or subject-based) for scientific publications as soon as possible and at the latest on publication • Open access to the deposited publication — via the repository — must be provided at the latest: • (i) on publication, if an electronic version is available for free via the publisher, or • (ii) within six months of publication Please consult within your organisation – UCL has a dedicated office supporting researchers with making their work open access

  16. Amelie Guisseau European Project Manager European Research & Innovation Office (ERIO) University College London Maple House, 149 Tottenham Court Rd, 7th Floor London W1T 7NF – United Kingdom a.guisseau@ucl.ac.uk Tel: +44 (0)20 7679 9635 Thank you for your attention!

More Related